Technology
Health
Pharmaceutical

VIVUS

$3.88
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.48 (14.12%) As of 2:18 PM EDT today
+$0.48 (14.12%) Today

Why Robinhood?

You can buy or sell VIVUS and other stocks, options, ETFs, and crypto commission-free!

About VVUS

VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Read More Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.

Employees
57
Headquarters
Campbell, California
Founded
1991
Market Cap
36.19M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
21.38K
High Today
$4.40
Low Today
$3.72
Open Price
$3.82
Volume
3.22M
52 Week High
$6.41
52 Week Low
$2.15

Collections

Technology
Health
Pharmaceutical
US
North America

VVUS News

ReutersAug 13

Edited Transcript of VVUS earnings conference call or presentation 6-Aug-19 8:30pm GMT

10

VVUS Earnings

-$1.17
-$0.81
-$0.46
-$0.10
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.99 per share
Actual
-$0.56 per share

More VVUS News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.